The Gemini Report – Investment Deep Dives

Comprehensive Investment Analysis: Eli Lilly and Company (LLY)

All investment deep dives on this site have been written by Google Gemini with light human editing. Nothing on this site constitutes investment advise. All materials on this site are for informational purposes only.

The Gemini Report - Investment Deep Dives
The Gemini Report – Investment Deep Dives
Comprehensive Investment Analysis: Eli Lilly and Company (LLY)
Loading
/

Executive Summary & Company Overview

Eli Lilly and Company (LLY) has undergone a profound strategic transformation, evolving from a diversified pharmaceutical firm into a highly focused innovator, primarily centered on cardiometabolic health, oncology, immunology, and neuroscience. The company operates as a single business segment dedicated to the discovery, development, manufacturing, and sale of human pharmaceutical products globally.1 This sharpened focus has culminated in a period of extraordinary growth, driven by the unprecedented success of its new class of incretin-based medicines for diabetes and obesity.

The company’s primary revenue streams are now dominated by its portfolio of recently launched medicines, with the dual GIP/GLP-1 receptor agonist, tirzepatide—marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management—serving as the principal growth engine.3 This franchise has positioned Eli Lilly in a duopolistic rivalry with Novo Nordisk, which markets the GLP-1 agonist semaglutide, for leadership in two of the largest and fastest-growing therapeutic markets in the world.5 Beyond its cardiometabolic franchise, the company generates significant revenue from key products in oncology, notably the CDK4 & 6 inhibitor Verzenio, and in immunology with the IL-17A antagonist Taltz.2

Geographically, the United States remains Eli Lilly’s most critical market, contributing approximately 64% of total revenue in 2023.2 The initial uptake and commercial success of Mounjaro and Zepbound have been overwhelmingly concentrated in the U.S., which continues to be the primary driver of the company’s top-line growth.3 Key international markets, including Europe, Japan, and China, represent significant future growth opportunities as the company secures regulatory approvals and reimbursement for its newer products.

Within the broader healthcare ecosystem, Eli Lilly is at the forefront of addressing some of the most pressing global health challenges, particularly the twin epidemics of obesity and diabetes.7 The company’s strategic initiatives extend beyond drug development, as evidenced by the launch of LillyDirect, a direct-to-consumer digital pharmacy platform. This move signals an intent to engage more directly with patients, potentially streamlining access to its medicines and gathering valuable real-world data, thereby challenging traditional pharmaceutical distribution models.9 The company’s current market position is a direct consequence of a multi-year strategic pivot that prioritized high-risk, high-reward R&D investments in areas of significant unmet medical need. This disciplined focus has enabled the development of deep scientific expertise and commercial synergies, creating a powerful competitive advantage but also introducing a significant degree of revenue concentration.

Industry Dynamics & Competitive Landscape

The global pharmaceutical industry is navigating a period of intense disruption and opportunity, shaped by powerful secular trends that are redefining business models and competitive advantages. Key industry dynamics include the rapid integration of artificial intelligence (AI) to accelerate drug discovery, persistent and intensifying pricing pressures from governments and payers, and the recurring threat of patent expirations on blockbuster products.

Macro-Industry Trends

The current operating environment is characterized by several overarching forces. Technologically, AI is becoming a transformative tool; industry forecasts suggest it could contribute to 30% of new drug discoveries by 2025, with the potential to reduce preclinical development timelines and costs by up to 50%.11 This shift necessitates significant investment in data science and computational capabilities to maintain a competitive edge in R&D.

Concurrently, the industry faces formidable regulatory and pricing headwinds. In the United States, the Inflation Reduction Act (IRA) has empowered Medicare to negotiate drug prices for the first time, representing a fundamental shift in the U.S. pricing landscape.7 Similarly, European authorities are exploring measures to reduce market exclusivity periods to control costs.7 These initiatives create a challenging backdrop for long-term revenue forecasting and margin stability.

Finally, the “patent cliff” remains a perennial industry challenge. Major pharmaceutical companies are bracing for an estimated $200 billion in revenue loss from patent expirations on key products in the coming years, including Merck’s top-selling oncology drug, Keytruda.14 This dynamic places a relentless emphasis on pipeline innovation to replace lost revenue and sustain growth.

Competitive Positioning and Moats

Eli Lilly’s competitive landscape is defined by a primary, intense rivalry in cardiometabolic diseases and broader competition across its other therapeutic areas.

The GLP-1 Duopoly: The most critical competitive arena is the global market for GLP-1-based therapies for diabetes and obesity, where Eli Lilly and Novo Nordisk have established a formidable duopoly. LLY’s tirzepatide (Mounjaro/Zepbound) competes directly with Novo Nordisk’s semaglutide (Ozempic/Wegovy).5 Clinical evidence provides Eli Lilly with a key competitive advantage; the head-to-head SURMOUNT-5 clinical trial demonstrated that Zepbound led to superior weight loss compared to Wegovy at maximum tolerated doses.17 However, Novo Nordisk benefits from a first-mover advantage, having established a strong market presence with Ozempic and Wegovy years before LLY’s entries. Both companies are engaged in a high-stakes race to innovate, with pipelines featuring next-generation assets, including oral formulations and novel combination therapies like Novo’s CagriSema (semaglutide/cagrilintide) and amycretin.19

Broader Pharmaceutical Peers: Beyond the GLP-1 space, Eli Lilly competes with a host of large-cap pharmaceutical peers, including Pfizer, Merck, AbbVie, and Johnson & Johnson.16 These companies possess highly diversified product portfolios, substantial financial resources, and extensive R&D capabilities. The high barrier to entry in the GLP-1 market was underscored by Pfizer’s recent clinical trial setbacks with its oral GLP-1 candidates due to safety and tolerability issues, highlighting the scientific lead held by Lilly and Novo Nordisk.22

Barriers to Entry: Eli Lilly’s competitive moat is built on three pillars:

  1. Intellectual Property: A robust patent estate protects its key products from generic competition. The core compound patent for tirzepatide extends to 2036 in the U.S. and 2037 in Europe, providing a long runway of market exclusivity.1
  2. R&D Prowess: A proven ability to innovate and execute complex clinical development programs, as demonstrated by the success of tirzepatide, creates a significant scientific barrier.
  3. Manufacturing Scale: The initial launches of GLP-1 therapies were characterized by widespread supply shortages, revealing that manufacturing capacity was the primary constraint on growth.25 In response, Eli Lilly has embarked on an aggressive capital investment cycle, committing over $50 billion since 2020 to expand its manufacturing footprint, primarily in the U.S..26 This massive investment is not merely an operational necessity to meet demand; it is a strategic maneuver to create a durable competitive advantage. By building out a vast and complex supply chain for injectable biologics, the company is raising the barrier to entry for smaller competitors who may develop clinically successful drugs but will lack the manufacturing infrastructure to compete on scale for many years.5

Financial Performance & Growth Analysis

An analysis of Eli Lilly’s financial results over the past five years reveals a company at a clear inflection point, with a dramatic acceleration in revenue growth and profitability driven by its new product portfolio. This growth has been accompanied by a significant increase in capital investment to support future expansion.

Historical Financial Performance

The company’s financial trajectory has been reshaped by the commercial success of its incretin franchise. Revenue grew at a compound annual growth rate (CAGR) of 16.4% from $24.5 billion in 2020 to $45.0 billion in 2024. The growth was particularly pronounced in 2023 and 2024, with year-over-year increases of 20% and 32%, respectively.1

This top-line expansion has translated into strong profitability. Operating income more than doubled from $6.5 billion in 2021 to $12.7 billion in 2024, while EBITDA grew from $9.7 billion to $16.6 billion over the same period. The company has consistently maintained high gross margins, which stood at 82.2% in Q4 2024, reflecting the premium pricing and value of its innovative medicines.3

Cash flow from operations has remained robust, reaching $8.8 billion in 2024.1 However, free cash flow has been constrained by a deliberate and massive ramp-up in capital expenditures. Capex surged from $1.8 billion in 2021 to $5.1 billion in 2024, directly reflecting the company’s strategy to build out its manufacturing capacity. This has resulted in a lower near-term free cash flow conversion, a strategic trade-off to secure long-term growth.

Table 1: 5-Year Financial Summary (2020-2024)

(in millions of USD)

Metric20202021202220232024
Total Revenue$24,539.8$28,318.4$28,541.4$34,124.1$45,042.7
Operating Income$7,229.9$6,505.7$7,092.3$6,971.8$12,680.4
Net Income$6,193.7$5,581.7$6,244.8$5,240.4$10,590.0
EBITDA$8,553.8$7,917.7$8,650.0$7,985.0$14,666.0
Cash from Operations$6,499.6$6,569.8$4,077.5$3,267.4$8,817.9
Capital Expenditures$(1,387.9)$(1,841.4)$(2,472.0)$(3,779.6)$(5,057.8)
Free Cash Flow$5,111.7$4,728.4$1,605.5$(512.2)$3,760.1
Sources:.1 EBITDA for 2020-2021 calculated as Operating Income + D&A from 10-K filings. FCF calculated as Cash from Operations – Capital Expenditures.

Revenue and R&D Analysis

The sources of Eli Lilly’s growth are highly concentrated. The Diabetes and Obesity therapeutic area has become the overwhelming contributor to the company’s revenue, growing from 52% of total sales in 2020 to approximately 69% in 2024. This highlights both the success of the incretin franchise and the increasing dependency on it. In contrast, the Oncology and Immunology segments have delivered steady but more modest growth.

Geographically, the U.S. market has been the engine of this expansion. U.S. revenue more than doubled from $14.2 billion in 2020 to an estimated $28.8 billion in 2024, while international revenue grew at a slower pace. This underscores the magnitude of the opportunity that remains as the company pursues broader global reimbursement and market access for Mounjaro and Zepbound.

The company’s investment in innovation remains substantial. R&D expenses have consistently represented over 20% of revenue, climbing from $6.1 billion in 2020 to over $9.3 billion in 2023.2 The high productivity of this investment is evidenced by the string of successful product launches in recent years, which have fueled the company’s growth.

Table 2: Revenue Breakdown by Therapeutic Area & Geography (2020-2023)

(in millions of USD)

Therapeutic Area2020202120222023
Diabetes & Obesity$12,834.4$13,188.1$14,464.8$19,667.6
Oncology$5,319.3$5,741.3$5,666.2$6,658.3
Immunology$2,461.9$3,360.8$3,344.6$3,797.5
Neuroscience$1,831.3$1,898.5$1,546.2$2,878.5
Other$3,092.8$4,130.0$3,519.7$1,122.2
Total Revenue$24,539.8$28,318.4$28,541.4$34,124.1
Geography2020202120222023
United States$14,229.3$16,811.0$18,190.0$21,791.0
Europe$4,187.7$4,776.8$4,299.2$6,174.7
Japan$2,583.1$2,367.0$1,747.3$1,672.6
China$1,116.9$1,661.4$1,452.8$1,539.7
Other Countries$2,422.7$2,702.2$2,852.0$2,946.2
Total Revenue$24,539.8$28,318.4$28,541.4$34,124.1
Sources:.2 Note: 2024 breakdowns are not fully available in filings.

Product Portfolio & Pipeline Analysis

Eli Lilly’s value proposition is anchored by a portfolio of high-growth products, led by the tirzepatide franchise, and supported by a deep and diverse clinical pipeline aimed at delivering the next wave of innovation. The long-term durability of its key revenue streams is reinforced by a favorable patent protection timeline for its most important assets.

Current Product Portfolio

The Tirzepatide Franchise (Mounjaro and Zepbound): This dual GIP/GLP-1 agonist is the company’s most valuable asset and the primary driver of its recent performance. For the full year 2024, Mounjaro, approved for type 2 diabetes, generated sales of $11.5 billion. Zepbound, approved for chronic weight management, achieved a remarkable $4.9 billion in sales in its first full year on the market, bringing the total franchise revenue to approximately $16.4 billion.32 The strong clinical profile of tirzepatide, which has demonstrated superior weight loss efficacy compared to competitor semaglutide in head-to-head studies, provides a strong foundation for continued market share gains.33

Other Blockbuster Drugs:

  • Verzenio (abemaciclib): An oral inhibitor of CDK4 & 6, Verzenio is a cornerstone of the company’s oncology portfolio. It has become a standard of care in certain types of breast cancer and continues to exhibit strong growth, with 2024 sales reaching $5.3 billion, a 37% increase over the prior year.3
  • Jardiance (empagliflozin): Co-marketed with Boehringer Ingelheim, this SGLT2 inhibitor is a leading treatment for type 2 diabetes and has expanded its indications to include heart failure, driving continued volume growth.3
  • Taltz (ixekizumab): An IL-17A antagonist for autoimmune conditions like psoriasis and psoriatic arthritis, Taltz remains a significant contributor to the immunology franchise.
  • Legacy Products: Trulicity (dulaglutide), once the company’s top-selling product, is now experiencing sales declines as patients and physicians transition to the more effective Mounjaro.3

Patent Expiration and Pipeline Analysis

A critical component of a pharmaceutical company’s long-term outlook is its ability to defend its innovations through intellectual property and replenish its portfolio through R&D.

Patent Outlook: Eli Lilly is well-positioned with regard to its key growth drivers. While some older products face nearer-term expirations, the tirzepatide franchise has a long period of market exclusivity. This extended runway is a fundamental pillar of the company’s long-term growth narrative.

Table 3: Key Product Patent Expiration Schedule

Product2024 Sales (USD Billions)Key U.S. Patent ExpirationKey EU Patent Expiration
Mounjaro/Zepbound$16.4 (est.)20362037
Verzenio$5.320312033
Trulicity$5.320272029
JardianceN/A (Alliance)20292029
Taltz$2.8 (est.)20302031
Sources:.1 Sales are for full-year 2024. Taltz 2024 sales estimated from 2023 results.

Clinical Pipeline: The company’s pipeline is robust, with numerous late-stage assets that have the potential to become significant new products and diversify its revenue base.

Table 4: Select Late-Stage Clinical Pipeline Assets (Phase 3 / Registration)

MoleculeTherapeutic AreaMechanism of ActionKey Expected Milestone
OrforglipronObesity / DiabetesOral GLP-1 Receptor AgonistRegulatory Submission (2025)
RetatrutideObesity / DiabetesGIP/GLP-1/Glucagon (GGG) Tri-agonistPhase 3 Data Disclosure (2025)
Donanemab / RemternetugNeuroscienceAmyloid Plaque Clearing AntibodyRegulatory Action (EU, 2025)
Pirtobrutinib (Jaypirca)OncologyNon-covalent BTK InhibitorRegulatory Submission (1L CLL, 2025)
ImlunestrantOncologyOral SERDRegulatory Action (mBC, 2025)
Mirikizumab (Omvoh)ImmunologyIL-23p19 AntibodyRegulatory Action (Crohn’s Disease, 2025)
Source:.36 CLL = Chronic Lymphocytic Leukemia; mBC = metastatic Breast Cancer.

The pipeline is strategically designed to build upon existing strengths and venture into new, high-potential areas. Orforglipron represents a critical next-generation asset to compete in the emerging oral anti-obesity market. Retatrutide has shown potential for even greater weight loss than tirzepatide in early studies, offering a potential successor product. The Alzheimer’s franchise (donanemab/remternetug) is a high-risk, high-reward endeavor that could open up a vast new market. In oncology, the company is expanding beyond Verzenio with assets like pirtobrutinib and imlunestrant. The company’s early-stage pipeline reflects a strategic push into novel modalities, including genetic medicines and radiopharmaceuticals, through both internal R&D and targeted business development.36

Recent Developments & Major Changes (2023-2025)

The period from 2023 through early 2025 has been one of the most transformative in Eli Lilly’s history, marked by blockbuster product launches, unprecedented investments in manufacturing, and a series of strategic acquisitions to fortify its future pipeline.

Commercial and Operational Milestones

The commercial trajectory of the tirzepatide franchise has been the dominant development. Zepbound was launched for chronic weight management in the U.S. in December 2023, following its FDA approval the prior month.38 The launch has been exceptionally strong, with Q4 2024 sales reaching $1.9 billion.39 To manage the immense demand and improve patient access, the company has introduced several initiatives, including the launch of its LillyDirect digital pharmacy platform and the release of single-dose vials, which offer a lower-priced option for self-pay patients.41 In late 2024, Zepbound received an expanded FDA approval for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, further broadening its market potential.10

To address the supply constraints that have accompanied this demand, Eli Lilly has initiated a historic expansion of its manufacturing capabilities. Since 2020, the company has committed over $50 billion to enhance its U.S. manufacturing footprint.26 This includes the construction of four new manufacturing sites announced in February 2025 and the acquisition of an injectable medicine facility in Wisconsin from Nexus Pharmaceuticals in April 2024.27 This aggressive build-out is a core component of the company’s long-term strategy to secure its supply chain and solidify its market leadership in injectable medicines.

Strategic Acquisitions and Partnerships

Eli Lilly has actively pursued business development to complement its internal R&D and enter new therapeutic modalities. This strategy can be characterized as a “buy and build” approach, where the company acquires platform technologies or early-stage assets and then invests heavily to develop them internally.

A prime example is the company’s entry into radiopharmaceuticals. In late 2023, Eli Lilly acquired POINT Biopharma for approximately $1.4 billion, gaining access to a pipeline of clinical and preclinical radioligand therapies for cancer.46 This was not an acquisition of a single late-stage product, but rather the purchase of a platform and the scientific expertise needed to build a new therapeutic capability. This initial acquisition was followed by further collaborations with companies like Aktis Oncology and AdvanCell in 2024 and 2025 to deepen its presence in the radiopharma space.48

Other notable transactions include the 2025 acquisition of Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program to bolster the oncology pipeline and a series of partnerships to access novel antibody discovery platforms, such as the collaboration with Alchemab for ALS treatments.48 This pattern of acquiring platform capabilities rather than just late-stage drugs is a more capital-efficient method of pipeline expansion and serves as a strategic hedge against future competitive threats in its core metabolic franchise.

Growth Opportunities & Strategic Initiatives

Eli Lilly’s future growth is underpinned by a clear set of strategic initiatives designed to capitalize on its current market leadership, expand its global reach, and deliver the next generation of innovative medicines from its pipeline.

Dominance in the Obesity Market: The most significant near- to medium-term growth opportunity lies in the global obesity market. This market is projected by analysts to expand dramatically, with estimates for annual sales ranging from $60 billion to as high as $150 billion by the early 2030s.49 With Zepbound’s clinically demonstrated efficacy advantage, Eli Lilly is exceptionally well-positioned to capture a substantial share of this burgeoning market. The recent label expansion into obstructive sleep apnea further solidifies Zepbound’s value proposition to patients and payers.10

International Expansion: While the United States has been the primary source of revenue for Mounjaro and Zepbound to date, international markets represent a vast and largely untapped opportunity. Securing reimbursement and broad market access in Europe, China, Japan, and other key regions will be a critical driver of growth over the next five to ten years. The company’s manufacturing expansion is a prerequisite for this global rollout, ensuring it can meet worldwide demand.3

Pipeline Advancement and Lifecycle Management: The company’s growth strategy extends beyond tirzepatide. The clinical pipeline contains several assets that could create subsequent waves of growth. The development of an effective oral GLP-1, orforglipron, is crucial for competing with oral formulations from rivals and capturing patients who prefer pills over injections. Retatrutide, a GGG tri-agonist, has shown the potential for even greater efficacy in early trials and could serve as a successor to tirzepatide, further extending the franchise’s lifecycle.36

Diversification into New Therapeutic Areas: Eli Lilly is making substantial long-term investments in areas outside of cardiometabolic health. The strategic push into oncology, particularly through the acquisition of the POINT Biopharma radioligand platform, represents a significant effort to build a new growth pillar.46 Similarly, the high-risk, high-reward programs in neuroscience for Alzheimer’s disease, if successful, could unlock a market of immense scale and diversify the company’s revenue base significantly.

Digital Health and Direct-to-Consumer Engagement: The launch of LillyDirect is a forward-looking strategic initiative that moves the company closer to the end patient.9 This platform has the potential to improve patient access and adherence, build brand loyalty, and provide the company with invaluable real-world data on treatment patterns and outcomes. Over time, this direct channel could also offer margin benefits by reducing reliance on intermediaries in the supply chain.

Capital Allocation & Shareholder Returns

Eli Lilly’s capital allocation strategy reflects a clear prioritization of reinvestment to fund its significant growth opportunities, while also demonstrating a strong commitment to returning capital to shareholders through dividends and share repurchases.

The company’s stated priorities for capital are, in order: supporting new product launches, aggressively expanding manufacturing capacity, and advancing its pipeline through both internal R&D and external business development.51 This growth-oriented framework is evident in the company’s financial decisions, particularly the substantial increase in capital expenditures and R&D spending in recent years.

Despite these immense reinvestment needs, the company has maintained and enhanced its shareholder return programs, signaling a high degree of confidence in its future cash flow generation.

Dividend Policy: Eli Lilly has a long and consistent history of paying dividends. In December 2024, the company announced a 15% increase in its quarterly dividend for 2025, marking the seventh consecutive year with a 15% raise.51 The annual dividend per share has grown steadily, from $2.96 in 2020 to $5.20 in 2024.52 The current dividend payout ratio of approximately 36% is sustainable and provides ample capacity for future increases, balancing shareholder returns with the need for internal investment.53

Share Repurchase Programs: The company has also become more aggressive with its share buyback activity. After completing a $5 billion repurchase program in the fourth quarter of 2024, the board immediately authorized a new, significantly larger $15 billion program, which management expects to execute over the subsequent three years.25 In Q4 2024 alone, the company returned approximately $2 billion to shareholders via buybacks.54

The decision to substantially increase both the dividend and the share repurchase authorization, concurrent with a capital expansion plan exceeding $50 billion, is a powerful signal of management’s conviction. It suggests a strong belief that the future operating cash flows generated by the incretin franchise will be more than sufficient to fund all strategic priorities—capex, R&D, M&A—while still allowing for a robust return of capital to shareholders. This sets a high bar for future performance but underscores the company’s optimistic long-term financial outlook.

Risk Assessment & Potential Headwinds

While Eli Lilly’s growth prospects are substantial, the company faces a range of significant risks that could impact its operations, financial results, and market position. These risks span competitive, regulatory, clinical, and operational domains and are detailed extensively in the company’s public filings.55

Concentration and Competitive Risk: A significant portion of Eli Lilly’s current revenue and the majority of its projected growth are dependent on a single molecule, tirzepatide, sold as Mounjaro and Zepbound.55 This concentration exposes the company to outsized risk in the event of unforeseen long-term safety issues, a decline in market uptake, or the emergence of a clinically superior competitor. The primary competitive threat comes from Novo Nordisk, which is developing its own next-generation obesity treatments, such as CagriSema and oral amycretin, that could challenge tirzepatide’s efficacy advantage.19

Regulatory and Political Risks: The pharmaceutical industry is subject to intense scrutiny over drug pricing. In the U.S., the Inflation Reduction Act (IRA) will subject top-selling drugs to price negotiations with Medicare, which could impact the long-term profitability of Lilly’s key products once they become eligible.7 Similar pricing pressures exist in major international markets. Furthermore, regulatory bodies could impose stricter requirements for clinical trials or marketing, and there is a rising threat from inadequately regulated counterfeit or illegally compounded versions of incretin medicines, which pose a risk to patient safety and the company’s reputation.55

Clinical Trial and Pipeline Setbacks: The future growth narrative is partially predicated on the successful development and commercialization of pipeline assets. Pharmaceutical R&D is inherently uncertain, and there is no guarantee of success.37 A failure of a key late-stage asset, such as the oral GLP-1 candidate orforglipron or the high-risk Alzheimer’s program, would represent a significant setback and could negatively impact investor sentiment and the company’s long-term growth profile.55

Manufacturing and Supply Chain Vulnerabilities: The execution of an unprecedented manufacturing expansion carries substantial operational risk. The company must manage the construction and validation of multiple new facilities on time and on budget. Any delays, quality control issues, or regulatory compliance problems at its manufacturing sites could disrupt product supply, preventing the company from meeting market demand and ceding share to competitors.55 Past regulatory scrutiny at facilities, such as the Branchburg, New Jersey plant, highlights the persistent nature of these challenges.57

Intellectual Property Risks: While the core patents for tirzepatide are long-dated, they will inevitably face legal challenges from generic and biosimilar manufacturers. An adverse ruling in a patent litigation case could shorten the period of market exclusivity and accelerate the onset of competition. The company also faces patent expirations on older blockbuster products, such as Trulicity in 2027, which will create revenue gaps that must be filled by newer products.35

Macroeconomic and International Risks: As a global entity, Eli Lilly is exposed to a variety of external risks, including unfavorable foreign currency exchange rate movements, global economic downturns that could constrain healthcare budgets, and geopolitical tensions, particularly concerning trade and supply chain dependencies with China.55

Valuation Analysis

Eli Lilly’s stock trades at a substantial valuation premium compared to its large-cap pharmaceutical peers, reflecting the market’s exceptionally high expectations for sustained, rapid growth driven by its leadership position in the obesity and diabetes markets. An analysis of key valuation multiples relative to historical levels and the broader industry is essential to contextualize its current market price.

Valuation Metrics and Peer Comparison

On virtually every standard valuation metric, Eli Lilly appears expensive relative to its competitors. As of mid-2025, its trailing twelve-month (TTM) P/E ratio stood at approximately 46x, a stark contrast to peers like Merck (13x), Pfizer (13x), and Johnson & Johnson (19x).58 Similarly, its TTM Enterprise Value to EBITDA (EV/EBITDA) multiple was approximately 33x, while most major pharmaceutical companies trade in a range of 7x to 15x.59 The company’s TTM Price-to-Sales (P/S) ratio of around 12x also significantly exceeds the typical industry range of 3x to 5x.60

This premium valuation is shared, to a degree, only by its primary competitor, Novo Nordisk, indicating that the market is assigning a unique scarcity value to companies with dominant and protected franchises in the high-growth GLP-1 market.

Table 5: Peer Group Financial & Valuation Comparison (Data as of mid-2025)

MetricEli Lilly (LLY)Novo Nordisk (NVO)Pfizer (PFE)Merck (MRK)AbbVie (ABBV)Johnson & Johnson (JNJ)
Market Cap (USD B)~$664~$222~$143~$210~$351~$425
LTM Revenue (USD B)~$55.5~$43.2~$62.5~$64.9~$54.3~$89.7
LTM Revenue Growth~38%~26%~-38%~1%~-7%~-5%
LTM EBITDA Margin~30%~50%~31%~38%~32%~34%
TTM P/E Ratio~45.7x~14.3x~13.3x~13.0x~18.4x~18.8x
LTM EV/EBITDA~32.8xN/A~7.6x~7.7xN/A~13.7x
TTM P/S Ratio~11.8x~5.1x~2.2x~3.3x~6.3x~4.7x
Sources:.30 Data is approximate based on latest available filings and market data as of mid-2025. NVO and ABBV EV/EBITDA not available in sources.

Historical Context and Interpretation

Eli Lilly’s current valuation multiples are not only elevated relative to peers but also reside at the higher end of their own 5- and 10-year historical ranges.58 The company’s EV/EBITDA multiple, for instance, expanded from 21.7x at the end of 2020 to a peak of 47.9x at the end of 2023, tracking the escalating success and market expectations for Mounjaro and Zepbound.59

The market is unequivocally pricing in a best-case scenario for Eli Lilly. The current valuation assumes:

  1. Sustained, multi-year, double-digit revenue growth.
  2. Dominant market share capture in the global obesity market.
  3. Maintenance of high gross and operating margins despite increasing pricing pressures.
  4. Successful execution of its massive manufacturing scale-up without significant delays or disruptions.
  5. Meaningful positive contributions from its late-stage clinical pipeline, potentially including success in challenging areas like Alzheimer’s disease.

This optimistic outlook leaves very little margin for error. Any significant deviation from this trajectory—whether from a competitive setback, a clinical trial failure, a manufacturing delay, or a more severe-than-expected regulatory pricing action—could lead to a substantial re-rating of the company’s valuation multiples. The core debate for investors is whether the company’s superior growth profile and pipeline optionality are sufficient to justify this premium and mitigate the inherent execution risks.

Key Questions for Further Investigation

This comprehensive analysis provides a detailed foundation for understanding Eli Lilly’s strategic position, financial performance, and market valuation. However, several critical questions remain that warrant ongoing monitoring and investigation to refine any investment thesis.

  1. How sustainable is Eli Lilly’s competitive advantage in diabetes and obesity? While tirzepatide currently holds an efficacy advantage, the durability of this lead is paramount. Close monitoring of Novo Nordisk’s pipeline, particularly the clinical data for CagriSema and amycretin, is essential to assess the long-term competitive dynamics. Furthermore, the company’s ability to execute its manufacturing expansion faster than its rivals will be a key determinant of market share capture.
  2. What is the realistic peak sales potential for tirzepatide across all indications? While market size estimates are vast, the actual realized revenue will depend on factors such as patient adherence rates, duration of therapy, and, most importantly, net price realization after rebates and discounts. Understanding how payer negotiations and government pricing actions, such as the IRA, will evolve is critical to modeling the franchise’s true long-term value.
  3. How effectively is the company managing its patent cliff challenges? Although the tirzepatide patent provides a long runway, the loss of exclusivity for Trulicity in 2027 will create a near-term headwind. The pace of conversion of Trulicity patients to Mounjaro and the growth of other products like Verzenio will determine how smoothly the company navigates this transition.
  4. What is the likelihood of successful pipeline execution in key therapeutic areas? The current valuation appears to assign significant value to pipeline assets. A rigorous, risk-adjusted assessment of the probability of success for key programs is necessary. In particular, the binary outcome of the Alzheimer’s program and the commercial potential of the oral GLP-1 and GGG tri-agonist programs require deep scrutiny.
  5. How might evolving healthcare policies impact long-term profitability? The global trend toward greater price controls on pharmaceuticals is undeniable. Investors must assess the potential impact of future legislation and regulatory actions on Eli Lilly’s pricing power and operating margins, as this represents one of the most significant long-term risks to the current investment case.

Works cited

  1. lly-20241231 – SEC.gov, accessed August 16, 2025, https://www.sec.gov/Archives/edgar/data/59478/000005947825000067/lly-20241231.htm
  2. Form 10-K for ELI Lilly Co filed 02/21/2024 – Eli Lilly Investors, accessed August 16, 2025, https://investor.lilly.com/static-files/9a5d6b82-282a-4a1c-b715-410a9059f69b
  3. Lilly reports full Q4 2024 financial results and provides 2025 guidance, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025
  4. Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-reports-strong-fourth-quarter-2023-financial-results-and
  5. NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now? | Nasdaq, accessed August 16, 2025, https://www.nasdaq.com/articles/nvo-vs-lly-which-obesity-powerhouse-stronger-bet-now
  6. Can anything threaten Novo and Lilly’s obesity market dominance? – PharmaVoice, accessed August 16, 2025, https://www.pharmavoice.com/news/novo-nordisk-eli-lilly-obesity-market-dominance-glp1/745823/
  7. Pharma trends 2024: Shaping the future landscape | ZS, accessed August 16, 2025, https://www.zs.com/insights/trends-shaping-pharmaceutical-landscape-2024-and-beyond
  8. Novo Nordisk Annual Report 2024, accessed August 16, 2025, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/novo-nordisk-annual-report-2024.pdf
  9. Year in Review | Eli Lilly and Company, accessed August 16, 2025, https://www.lilly.com/about/year-in-review
  10. Lilly Launches Full Zepbound Dose Access for Obesity Through LillyDirect Self-Pay Program – Pharmaceutical Executive, accessed August 16, 2025, https://www.pharmexec.com/view/lilly-launches-full-zepbound-dose-access-obesity-lillydirect-self-pay-program
  11. How 2025 can be a pivotal year of progress for Biopharma | World …, accessed August 16, 2025, https://www.weforum.org/stories/2025/01/2025-can-be-a-pivotal-year-of-progress-for-pharma/
  12. Pharma industry trends: PwC, accessed August 16, 2025, https://www.pwc.com/us/en/industries/pharma-life-sciences/pharmaceutical-industry-trends.html
  13. Top Regulatory News of 2024, accessed August 16, 2025, https://www.theregreview.org/2025/01/03/top-regulatory-news-of-2024/
  14. Global Life Sciences Industry Trends 2025 – Indegene, accessed August 16, 2025, https://www.indegene.com/what-we-think/reports/global-life-sciences-industry-trends-2025
  15. Pharma 50: The top pharma companies in the world for 2025, accessed August 16, 2025, https://www.drugdiscoverytrends.com/pharma-50-the-50-largest-pharmaceutical-companies-in-the-world-for-2025/
  16. Who are the main competitors of Eli Lilly? – Patsnap Synapse, accessed August 16, 2025, https://synapse.patsnap.com/article/who-are-the-main-competitors-of-eli-lilly
  17. Zepbound or Wegovy? Head-to-Head Trial Says One Is Better for Weight Loss – Health, accessed August 16, 2025, https://www.health.com/zepbound-or-wegovy-better-for-weight-loss-11737253
  18. Zepbound outduels Wegovy in weight-loss clinical trial – Cornell Chronicle, accessed August 16, 2025, https://news.cornell.edu/stories/2025/05/zepbound-outduels-wegovy-weight-loss-clinical-trial
  19. 5 Oral Obesity Drugs Challenging Lilly’s Orforglipron – BioSpace, accessed August 16, 2025, https://www.biospace.com/drug-development/5-oral-obesity-drugs-challenging-lillys-orforglipron
  20. R&D pipeline – Novo Nordisk, accessed August 16, 2025, https://www.novonordisk.com/science-and-technology/r-d-pipeline.html
  21. AbbVie (ABBV) Investor Relations Material – Quartr, accessed August 16, 2025, https://quartr.com/companies/abbvie-inc_6137
  22. Pfizer’s embattled obesity program loses another GLP-1 drug – Fierce Biotech, accessed August 16, 2025, https://www.fiercebiotech.com/biotech/pfizers-embattled-obesity-program-loses-another-glp-1-drug
  23. Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity, accessed August 16, 2025, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r
  24. Zepbound patent expiration – Pharsight, accessed August 16, 2025, https://pharsight.greyb.com/drug/zepbound-patent-expiration
  25. Eli Lilly Powers Investor Confidence with New $15B Share Buyback Program – Xtalks, accessed August 16, 2025, https://xtalks.com/eli-lilly-powers-investor-confidence-with-new-15b-share-buyback-program-4007/
  26. Statement: America’s leading role in biopharmaceutical innovation | Eli Lilly and Company, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/statement-americas-leading-role-biopharmaceutical-innovation
  27. Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-plans-more-double-us-manufacturing-investment-2020
  28. Can Smaller Companies Compete in the GLP-1 Market? – American Century Investments, accessed August 16, 2025, https://www.americancentury.com/insights/small-glp-1-companies/
  29. lly-20201231 – SEC.gov, accessed August 16, 2025, https://www.sec.gov/Archives/edgar/data/59478/000005947821000083/lly-20201231.htm
  30. Eli Lilly EBITDA 2010-2025 | LLY – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/LLY/eli-lilly/ebitda
  31. Eli Lilly and Company 2022 Annual Report on … – Eli Lilly Investors, accessed August 16, 2025, https://investor.lilly.com/static-files/2f9b7bb1-f955-448d-baa2-c4343d39ee62
  32. Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 | AP News, accessed August 16, 2025, https://apnews.com/article/eli-lilly-fourth-quarter-mounjaro-zepbound-ca026922525a9e3abb1b75d329628bef
  33. Ozempic vs. Mounjaro: How Do They Compare? – Scripps Health, accessed August 16, 2025, https://www.scripps.org/news_items/7859-ozempic-vs-mounjaro-how-do-they-compare
  34. Lilly’s Mounjaro Helps Patients Lose More Weight Than Novo’s Ozempic: Study – BioSpace, accessed August 16, 2025, https://www.biospace.com/drug-development/lillys-mounjaro-helps-patients-lose-more-weight-than-novos-ozempic-study
  35. 8 key drug patents expiring soon — and what it means for the market – Quartz, accessed August 16, 2025, https://qz.com/drug-patent-expirations-prices-ozempic-keytruda-1851770073
  36. Earnings Presentation – Eli Lilly Investors, accessed August 16, 2025, https://investor.lilly.com/static-files/b7c7e82b-e667-42ba-827c-1faecba3e4c8
  37. Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-highlights-innovation-based-growth-strategy-and-pipeline
  38. Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/zepboundtm-tirzepatide-now-available-us-pharmacies-adults-living
  39. Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance | Eli Lilly and Company – Eli Lilly Investors, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-provides-update-2024-revenue-guidance-announces-2025
  40. Eli Lilly logs massive Q4 revenue jump—but it’s not just thanks to Mounjaro and Zepbound, accessed August 16, 2025, https://www.fiercepharma.com/pharma/eli-lillys-very-beatable-2025-guidance-should-ease-investor-sentiment-after-recent-glp-1
  41. Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions | Eli Lilly and Company, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-offer-all-approved-doses-zepbound-tirzepatide-single-dose
  42. Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-launches-additional-zepbound-vial-doses-and-offers-new
  43. Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-releases-zepboundr-tirzepatide-single-dose-vials-expanding
  44. Lilly Acquires New Injectable Medicine Manufacturing Facility from Nexus Pharmaceuticals, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-acquires-new-injectable-medicine-manufacturing-facility
  45. Indy-based pharmaceutical giant Eli Lilly to invest roughly $27 billion in manufacturing, accessed August 16, 2025, https://www.wfyi.org/news/articles/indy-based-pharmaceutical-giant-eli-lilly-to-invest-roughly-27-billion-in-manufacturing
  46. Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies | Eli Lilly and Company, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-point-biopharma-expand-oncology-capabilities-next
  47. Lilly Completes Acquisition of POINT Biopharma | Eli Lilly and Company, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-point-biopharma
  48. Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree? – Labiotech.eu, accessed August 16, 2025, https://www.labiotech.eu/trends-news/eli-lilly-partnerships-surge-2025/
  49. Obesity Treatment Market Size, Share | Industry Report, 2030 – Grand View Research, accessed August 16, 2025, https://www.grandviewresearch.com/industry-analysis/obesity-treatment-devices-and-therapeutics-market
  50. The Exponential Growth of Obesity Drugs – Morgan Stanley, accessed August 16, 2025, https://www.morganstanley.com/insights/articles/weight-loss-medication-market-unstoppable-growth
  51. Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase, accessed August 16, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-announces-new-15-billion-share-repurchase-program-and
  52. Dividends & Stock Splits | Eli Lilly and Company, accessed August 16, 2025, https://investor.lilly.com/stock-information/dividends-splits
  53. Eli Lilly and Company (LLY) Dividend Date & History – Koyfin, accessed August 16, 2025, https://www.koyfin.com/company/lly/dividends/
  54. Earnings Presentation – Eli Lilly Investors, accessed August 16, 2025, https://investor.lilly.com/static-files/09d156c0-f88d-420b-b5f1-1ed2b417461b
  55. ELI LILLY AND COMPANY, accessed August 16, 2025, https://investor.lilly.com/static-files/ff06ed54-9f64-4b7f-8529-c0278d635eac
  56. Eli Lilly (Nasdaq: LLY) – Current Students – The University of Iowa, accessed August 16, 2025, https://students.tippie.uiowa.edu/sites/students.tippie.uiowa.edu/files/2025-04/s25_LLY.pdf
  57. Eli Lilly confirms plan to sell New Jersey plant – Fierce Pharma, accessed August 16, 2025, https://www.fiercepharma.com/pharma/eli-lilly-confirms-plans-sell-nj-plant-amid-27b-manufacturing-project
  58. LLY – ELI LILLY PE ratio, current and historical analysis – FullRatio, accessed August 16, 2025, https://fullratio.com/stocks/nyse-lly/pe-ratio
  59. Eli Lilly and Co (BIT:1LLY) EV / EBITDA – Investing.com, accessed August 16, 2025, https://ng.investing.com/pro/BIT:1LLY/explorer/ev_to_ebitda_ltm
  60. Eli Lilly P/S Ratio 2010-2025 | LLY – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/LLY/eli-lilly/price-sales
  61. Eli Lilly (LLY) – P/S ratio – Companies Market Cap, accessed August 16, 2025, https://companiesmarketcap.com/eli-lilly/ps-ratio/
  62. Eli Lilly – 51 Year Dividend History | LLY – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/LLY/eli-lilly/dividend-yield-history
  63. Novo Nordisk EBITDA Margin 2010-2025 | NVO – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/ebitda-margin
  64. Novo Nordisk EBITDA 2010-2025 | NVO – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/ebitda
  65. Pfizer Inc (NYSE:PFE) EV / EBITDA – Investing.com, accessed August 16, 2025, https://www.investing.com/pro/NYSE:PFE/explorer/ev_to_ebitda_ltm
  66. Pfizer EBITDA 2010-2025 | PFE – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/PFE/pfizer/ebitda
  67. Merck & Company Inc (NYSE:MRK) EV / EBITDA – Investing.com, accessed August 16, 2025, https://www.investing.com/pro/NYSE:MRK/explorer/ev_to_ebitda_ltm
  68. Merck EBITDA 2010-2025 | MRK – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/MRK/merck/ebitda
  69. AbbVie EBITDA 2010-2025 | ABBV – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/ABBV/abbvie/ebitda
  70. Johnson & Johnson (BRSE:000943981) EV / EBITDA – Investing.com, accessed August 16, 2025, https://www.investing.com/pro/BRSE:000943981/explorer/ev_to_ebitda_ltm
  71. Johnson & Johnson EBITDA 2010-2025 | JNJ – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/JNJ/johnson-johnson/ebitda
  72. Novo Nordisk P/S Ratio 2010-2025 | NVO – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/NVO/novo-nordisk/price-sales
  73. Novo Nordisk (NVO) – P/S ratio – Companies Market Cap, accessed August 16, 2025, https://companiesmarketcap.com/novo-nordisk/ps-ratio/
  74. Pfizer P/S Ratio 2010-2025 | PFE – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/PFE/pfizer/price-sales
  75. Merck (MRK) – P/S ratio – Companies Market Cap, accessed August 16, 2025, https://companiesmarketcap.com/merck/ps-ratio/
  76. AbbVie Price to Sales Ratio 2010-2025 | ABBV – Macrotrends, accessed August 16, 2025, https://macrotrends.net/stocks/charts/ABBV/abbvie/price-sales
  77. Johnson & Johnson P/S Ratio 2010-2025 | JNJ – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/JNJ/johnson-johnson/price-sales
  78. Johnson & Johnson (JNJ) – P/S ratio – Companies Market Cap, accessed August 16, 2025, https://companiesmarketcap.com/johnson-and-johnson/ps-ratio/
  79. Eli Lilly PE Ratio 2010-2025 | LLY – Macrotrends, accessed August 16, 2025, https://www.macrotrends.net/stocks/charts/LLY/eli-lilly/pe-ratio